GC4711 + SBRT for Pancreatic Cancer

Recruiting in Palo Alto (17 mi)

+37 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Galera Therapeutics, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called GC4711 to see if it can improve the results of a precise radiation therapy for patients whose cancer cannot be easily removed by surgery. The goal is to find out if adding GC4711 makes the radiation treatment more effective. This could help patients with difficult-to-remove cancers live longer.

Research Team

Jon Holmlund, MD

Principal Investigator

Chief Medical Officer

Eligibility Criteria

Inclusion Criteria

You have been diagnosed with pancreatic cancer confirmed by a tissue sample or, if not possible, by a fluid sample.

You are able to perform daily activities without being limited by your health.

Your organs are working properly.

Exclusion Criteria

You have a stomach or small intestine ulcer that is not under control within the last 30 days.

The tumor is clearly invading the inside of the bowel or stomach, as seen during an endoscopy.

You have a type of cancer that is not prostate cancer and it is not under control.

Treatment Details

Interventions

• GC4711 (Radiosensitizer)
• Placebo (Chemotherapy)

Participant Groups

Group I: Arm A Active GC4711 Experimental Treatment 1 Intervention

Group II: Arm B Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Galera Therapeutics, Inc.

Lead Sponsor

Trials

17

Recruited

1,400+